163 related articles for article (PubMed ID: 24390274)
1. Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.
Hamilton AS; Fleming ST; Wang D; Goodman M; Wu XC; Owen JB; Lo M; Ho A; Anderson RT; Thompson T
Am J Clin Oncol; 2016 Feb; 39(1):55-63. PubMed ID: 24390274
[TBL] [Abstract][Full Text] [Related]
2. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
[TBL] [Abstract][Full Text] [Related]
3. Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina.
Ellis SD; Blackard B; Carpenter WR; Mishel M; Chen RC; Godley PA; Mohler JL; Bensen JT
Cancer; 2013 Jun; 119(12):2282-90. PubMed ID: 23575751
[TBL] [Abstract][Full Text] [Related]
4. Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
Fang P; He W; Gomez DR; Hoffman KE; Smith BD; Giordano SH; Jagsi R; Smith GL
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):748-757. PubMed ID: 28366580
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
[TBL] [Abstract][Full Text] [Related]
6. Trends and black/white differences in treatment for nonmetastatic prostate cancer.
Klabunde CN; Potosky AL; Harlan LC; Kramer BS
Med Care; 1998 Sep; 36(9):1337-48. PubMed ID: 9749657
[TBL] [Abstract][Full Text] [Related]
7. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
8. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D
Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748
[TBL] [Abstract][Full Text] [Related]
9. Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002.
Rose AJ; Backus BM; Gershman ST; Santos P; Ash AS; Battaglia TA
Med Care; 2007 May; 45(5):440-7. PubMed ID: 17446830
[TBL] [Abstract][Full Text] [Related]
10. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns for older veterans with localized prostate cancer.
Hoffman RM; Shi Y; Freedland SJ; Keating NL; Walter LC
Cancer Epidemiol; 2015 Oct; 39(5):769-77. PubMed ID: 26228494
[TBL] [Abstract][Full Text] [Related]
12. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I
J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735
[No Abstract] [Full Text] [Related]
13. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.
Wu XC; Lund MJ; Kimmick GG; Richardson LC; Sabatino SA; Chen VW; Fleming ST; Morris CR; Huang B; Trentham-Dietz A; Lipscomb J
J Clin Oncol; 2012 Jan; 30(2):142-50. PubMed ID: 22147735
[TBL] [Abstract][Full Text] [Related]
14. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
Gray PJ; Lin CC; Cooperberg MR; Jemal A; Efstathiou JA
Eur Urol; 2017 May; 71(5):729-737. PubMed ID: 27597241
[TBL] [Abstract][Full Text] [Related]
15. Active treatment in low-risk prostate cancer: a population-based study.
Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
[TBL] [Abstract][Full Text] [Related]
16. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
Mahase SS; D'Angelo D; Kang J; Hu JC; Barbieri CE; Nagar H
JAMA Netw Open; 2020 Feb; 3(2):e1920471. PubMed ID: 32022878
[TBL] [Abstract][Full Text] [Related]
17. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.
Parikh RB; Robinson KW; Chhatre S; Medvedeva E; Cashy JP; Veera S; Bauml JM; Fojo T; Navathe AS; Malkowicz SB; Mamtani R; Jayadevappa R
JAMA Netw Open; 2020 Sep; 3(9):e2018318. PubMed ID: 32986109
[TBL] [Abstract][Full Text] [Related]
18. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.
Bagley AF; Anscher MS; Choi S; Frank SJ; Hoffman KE; Kuban DA; McGuire SE; Nguyen QN; Chapin B; Aparicio A; Pezzi TA; Smith GL; Smith BD; Hess K; Tang C
JAMA Netw Open; 2020 Mar; 3(3):e201255. PubMed ID: 32191331
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
20. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States).
Morris CR; Snipes KP; Schlag R; Wright WE
Cancer Causes Control; 1999 Dec; 10(6):503-11. PubMed ID: 10616820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
